CREATE
TRANSFORMATIVE
MEDICINES
A global leader in innovative solutions for the discovery, development, and manufacture of novel nanoparticle medicines.
 

 

 

Every Stage
of Development

Announcing Daiichi Sankyo Precision NanoSystems' Newest Clinical Client

 

Daiichi Sankyo has signed a license agreement for use of the NanoAssemblr GMP System configuring a customized microfluidics-based GMP System that is fit-for-purpose and stage appropriate. Daiichi Sankyo is a customer of PNI using the NanoAssemblr suite of instruments including the Benchtop and the Blaze to perform research and development to create innovative medicines to address unmet medical needs. Read more... 

 

With over 280 systems placed worldwide, PNI's proprietary microfluidics technology, the NanoAssemblr platform is the industry leader platform used by over 95 pharma/biotech and 90 academic customers in the areas of gene and cell therapy, cancerrare diseases, and  infectious diseases.

 

We provide a wide range of expertise in formulation and clinical solutions, a proprietary platform and reagents.

 

 

Formulation Solutions Formulation Solutions Formulation Solutions
Rapidly prepare low-volume nanoparticle formulations with the push of a button on the Spark™ or learn how Formulation Solutions can help with proof-of-concept nanoparticle formulations.
Optimize a wide range of nanomedicine formulations with the NanoAssemblr® Benchtop or the Blaze  depending on your volumes to allow you to gather the data on the effectiveness, required dosing and safety of a new therapy.
Scalable manufacturing is a significant challenge to making revolutionary medicine and  Clinical Solution  is ready to assist you in your nanoparticle manufacturing process development.
You're In Good Company
<

 

  • “The NanoAssemblr® Blaze™ from Precision NanoSystems is very good for the rapid scale-up of nanoparticle-based formulations. We were able to seamlessly transition our formulation developed on the NanoAssemblr Benchtop to the Blaze instrument and make large scale batches on the Blaze. The Blaze instrument has saved us time, effort and precious materials.” - Muthusamy Jayaraman Senior Director, Head of Non-Viral Delivery at CRISPR Therapeutics
  • "As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use."  - Don Enns, Vice President of Evonik Vancouver Laboratories
  • "We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens."- Frank Slack, Director of the Harvard Medical School Initiative for RNA Medicine (HIRM) at BIDMC
  • "Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr® GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture of nanoparticle-based medicines"  - Kristin DeFife, Ph.D., Vice President and Head of US Operations of Ajinomoto Bio-Pharma Services
>

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch
Technology

Our technology provides a seamless path forward to larger experimental studies, all the way to the clinic: low volume prototype formulations are easily scaled-up using larger instruments of the NanoAssemblr® family, which provides microfluidic mixing and manufacturing of nanoparticles.

 


Mixtures
Areas of Interest
Nanomedicines span many areas of interest. Explore resourceslike papers, application notes, scientific posters, webinars and more to see how nanotechnology is transforming medicine. 
Particles
over
70%
of top pharmaceutical companies work with PNI
200+

instruments are installed

worldwide

80+
biopharmaceutical labs use NanoAssemblr® instruments for nanomedicine drug development
Innovations that accelerate the drug development journey and enable the production of more sophisticated and powerful nanomedicines is our passion. We don’t do it alone, we pursue strategic collaborations that enable researchers to move quickly in the drug development process. Contact our Business Development Team.

 

 

 

 

 

PNI Feature in BioWorld

 

"As we bite off different problems and succeed on those, we can leverage those technologies," CEO Taylor explains. "We like to think that we're democratizing and lowering the barrier for people to get into these important technologies."

Evonik Collaboration

 

PNI announces a manufacturing collaboration agreement with Evonik for the tech transfer of the NanoAssemblr® system to Evonik Canada for late-stage clinical research.

License Agreement with Entos Pharmaceuticals

 

Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr® platform for scale-up and GMP manufacturing of nanomedicines.

 

Upcoming Events See All

July
21 - 24
2019

Controlled Release Society Annual Meeting & Exposition (CRS 2019)

We invite you to join us in Valencia, Spain for the 46th Controlled Release Society Annual Meeting & Exposition also referred to as CRS 2019. Held in the Palacio de Congresos de València from July 21st-24th, this premier event sports a powerful lineup of presenters i...

September
09 - 10
2019

American DDF Summit

Held in Boston, American DDF Summit brings innovative solutions to the greatest challenges in pharmaceutical development. Covering both small molecules and biologics, you’ll be able find new technologies,concepts and case studies in areas such as formulation design for po...

September
22 - 24
2019

NanoDDS

Hosted at the Massachusetts University of Technology, NanoDDS highlights new groundbreaking discoveries and developments in nanomedicine and drug delivery. Revolutionary advances in this area require collaboration among researchers working in a diverse array of fields including ...

Resource Center

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, et al.

Read More

Publication - Summary

May 17, 2019

Science Immunology

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

N. Kose, J.M. Fox, G. Sapparapu, et al.

Read More

Publication - Summary

April 04, 2019

The Journal of Neuroscience

PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, R. Graham, D.S. Kirkpatrick, M...

Read More

Publication - Summary

February 07, 2019

Nano Research

Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast can...

C. Zhang, X. Zhang, W. Zhao, C. Zeng, W. Li, B. Li, X. Luo, J. Li, J. Jiang, B. Deng, D.W. McComb, Y. Dong

Read More

Application Note

January 16, 2019

mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials

Read More PDF

Publication - Summary

September 24, 2018

Nucleic Acid Therapeutics

MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct

R. Jain, JP. Frederick, EY. Huang, KE. Burke, DM. Mauger, EA. Andrianova, SJ. Farlow, S. Siddiqui, J. Pimentel, K. Cheun...

Read More
Resource Center

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.

MENU
X